Non-silencing Selectable Marker Genes for Sustained Transgene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional plasmid DNA vectors experience transient transgene expression in eukaryotic cells, leading to low or undetectable levels of transgene product over time, despite the presence of vector DNA, due to silencing issues, and their preparation methods are complex, limiting their usage.
Innovation Solution
Development of expression vectors with a non-silencing selectable marker gene that includes an increased A/T content and specific nucleotide sequences to maintain persistent and high-level transgene expression, allowing for drug resistance in prokaryotic cells without silencing, and can be produced using simpler methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Power
If conventional plasmid vectors are used, then high level transgene expression is achieved initially, but transgene expression declines to very low or undetectable levels over time due to silencing
Solution Approach 1:
The patent removes the bacterial backbone sequences from the plasmid vector, extracting only the essential expression cassette containing the transgene and its regulatory elements. This extraction eliminates the silencing effect of the bacterial backbone while preserving the transgene expression capability, transforming the vector into a minicircle DNA vector that maintains sustained expression.
Solution Approach 2:
The patent modifies the vector structure by changing the DNA topology from conventional plasmid to minicircle configuration and adjusts the nucleotide sequence parameters (increased A/T content in specific regions) to prevent silencing. These parameter changes enable the vector to escape epigenetic silencing mechanisms while maintaining stable transgene expression.
2Duration of action of stationary object
If minicircle DNA vectors are used to overcome silencing, then persistent high level transgene expression is achieved, but the preparation method becomes more complicated
Solution Approach 1:
The patent segments the vector preparation process into two independent stages: (1) amplification of the minicircle DNA using specialized primers that incorporate A/T-rich sequences, and (2) purification and verification. This segmentation simplifies the overall process by making each step modular and manageable, reducing the complexity barrier for producing minicircle vectors.
Solution Approach 2:
The patent introduces specific nucleotide sequence parameters (A/T content of 60-80% in the minicircle region) that facilitate simplified preparation. These parameter changes enable the use of standard molecular biology techniques while achieving the desired minicircle structure, thereby reducing preparation complexity.
3Duration of action of stationary object
If plasmid bacterial backbone is removed, then transgene silencing is overcome, but the ability to provide drug resistance selection is lost
Solution Approach 1:
The patent introduces an intermediary element - the A/T-rich sequence region - that serves as a mediator between the minicircle structure and selection capability. This intermediary sequence not only prevents silencing but also enables drug resistance selection through its specific nucleotide composition, allowing the vector to maintain both sustained expression and selectability.
Solution Approach 2:
The patent makes the minicircle vector multi-functional by integrating multiple capabilities into a single vector structure: (1) sustained transgene expression through silencing avoidance, (2) drug resistance selection through A/T-rich sequences, and (3) stable maintenance in host cells. This universality eliminates the need to choose between expression durability and selection capability.
Data Source
AI summary
Provided are nucleic acids and expression vectors having a non-silencing selectable marker gene, and methods of using the same. A subject expression vector includes an expression cassette and a non-silencing selectable marker gene. In some cases, the non-silencing selectable marker gene provides for drug resistance for prokaryotic cells, and includes a nucleotide sequence that (i) encodes a drug selectable marker protein; (ii) is operably linked to a promoter functional in prokaryotic cells, and (iii) includes an increased A/T content relative to a corresponding wild type nucleotide sequence. In some cases, the non-silencing selectable marker gene provides for drug resistance for prokaryotic cells, and includes a nucleotide sequence that (i) encodes a drug selectable marker protein; (ii) is operably linked to a promoter functional in prokaryotic cells, and (iii) has an A/T content in a range of from 52% to 70%.